Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.

Valianatos G, Valcikova B, Growkova K, Verlande A, Mlcochova J, Radova L, Stetkova M, Vyhnakova M, Slaby O, Uldrijan S.

PLoS One. 2017 Oct 3;12(10):e0185801. doi: 10.1371/journal.pone.0185801. eCollection 2017.

2.

Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells.

Krishnamoorthy A, Witkowski A, Ryan RO.

J Nanomed Nanotechnol. 2017 Aug;8(4). pii: 454. doi: 10.4172/2157-7439.1000454. Epub 2017 Aug 23.

3.

Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.

Carr MI, Jones SN.

Transl Cancer Res. 2016 Dec;5(6):707-724. doi: 10.21037/tcr.2016.11.75.

4.

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.

J Hematol Oncol. 2017 Jul 3;10(1):133. doi: 10.1186/s13045-017-0500-5. Review.

5.

Evidence of a prion-like transmission of p53 amyloid in Saccharomyces cerevisiae.

Sengupta S, Maji SK, Ghosh SK.

Mol Cell Biol. 2017 Jun 19. pii: MCB.00118-17. doi: 10.1128/MCB.00118-17. [Epub ahead of print]

PMID:
28630281
6.

Mutation spectrum of RB1 mutations in retinoblastoma cases from Singapore with implications for genetic management and counselling.

Tomar S, Sethi R, Sundar G, Quah TC, Quah BL, Lai PS.

PLoS One. 2017 Jun 2;12(6):e0178776. doi: 10.1371/journal.pone.0178776. eCollection 2017.

7.

Inhibition of glioblastoma growth and invasion by 125I brachytherapy in rat glioma model.

Chen F, Wang D.

Am J Transl Res. 2017 May 15;9(5):2243-2254. eCollection 2017.

8.

Tumorigenesis promotes Mdm4-S overexpression.

Pant V, Larsson CA, Aryal N, Xiong S, You MJ, Quintas-Cardama A, Lozano G.

Oncotarget. 2017 Apr 18;8(16):25837-25847. doi: 10.18632/oncotarget.15552.

9.

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.

Xie C, Freeman MJ, Lu H, Wang X, Forster CL, Sarver AL, Hallstrom TC.

Oncotarget. 2017 Jun 13;8(24):38084-38098. doi: 10.18632/oncotarget.16970.

10.

Reviving the guardian of the genome: Small molecule activators of p53.

Nguyen D, Liao W, Zeng SX, Lu H.

Pharmacol Ther. 2017 Oct;178:92-108. doi: 10.1016/j.pharmthera.2017.03.013. Epub 2017 Mar 27. Review.

PMID:
28351719
11.

Performance of a docking/molecular dynamics protocol for virtual screening of nutlin-class inhibitors of Mdmx.

Bharatham N, Finch KE, Min J, Mayasundari A, Dyer MA, Guy RK, Bashford D.

J Mol Graph Model. 2017 Jun;74:54-60. doi: 10.1016/j.jmgm.2017.02.014. Epub 2017 Feb 24.

PMID:
28351017
12.

Targeting MDM4 Splicing in Cancers.

Bardot B, Toledo F.

Genes (Basel). 2017 Feb 20;8(2). pii: E82. doi: 10.3390/genes8020082. Review.

13.

Roles of pRB in the Regulation of Nucleosome and Chromatin Structures.

Uchida C.

Biomed Res Int. 2016;2016:5959721. doi: 10.1155/2016/5959721. Epub 2016 Dec 22. Review.

14.

Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.

Hernández-Monge J, Rousset-Roman AB, Medina-Medina I, Olivares-Illana V.

Genes Cancer. 2016 Sep;7(9-10):278-287. doi: 10.18632/genesandcancer.120. Review.

15.

The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Xiong S, Pant V, Zhang Y, Aryal NK, You MJ, Kusewitt D, Lozano G.

J Pathol. 2017 Mar;241(4):501-510. doi: 10.1002/path.4854. Epub 2017 Jan 6.

PMID:
27925213
16.

The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target.

Fierabracci A, Pellegrino M.

Int J Mol Sci. 2016 Nov 25;17(12). pii: E1975. Review.

17.

MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.

Qi DL, Cobrinik D.

Oncogene. 2017 Mar 30;36(13):1760-1769. doi: 10.1038/onc.2016.350. Epub 2016 Oct 17.

18.

The associations between MDM4 gene polymorphisms and cancer risk.

Wang MJ, Luo YJ, Shi ZY, Xu XL, Yao GL, Liu RP, Zhao H.

Oncotarget. 2016 Aug 23;7(34):55611-55623. doi: 10.18632/oncotarget.10877.

19.

Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.

Walter RF, Vollbrecht C, Werner R, Mairinger T, Schmeller J, Flom E, Wohlschlaeger J, Barbetakis N, Paliouras D, Chatzinikolaou F, Adamidis V, Tsakiridis K, Zarogoulidis P, Trakada G, Christoph DC, Schmid KW, Mairinger FD.

J Cancer. 2016 Sep 13;7(13):1915-1925. eCollection 2016.

20.

The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells.

Matijasevic Z, Krzywicka-Racka A, Sluder G, Gallant J, Jones SN.

Oncogenesis. 2016 Oct 3;5(10):e262. doi: 10.1038/oncsis.2016.62.

Supplemental Content

Support Center